Business

Announcement on the Voluntary Disclosure of the Acceptance of the Supplemental Drug Application for the Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

Announcement on the Voluntary Disclosure of the Acceptance of the Supplemental Drug Application for the Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

articleCansino Biologics, Inc. Class ANovember 26, 20244/news/announcement-on-the-voluntary-disclosure-of-the-acceptance-of-the-supplemental-drug-application-for-the-group-acyw135-meningococcal-polysaccharide-conjugate-vaccine-crm197-vector
Announcement on the Voluntary Disclosure of the Acceptance of the Supplemental Drug Application for the Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

About this update from Cansino Biologics, Inc. Class A

Announcement on the Voluntary Disclosure of the Acceptance of the Supplemental Drug Application for the Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)The abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Cansino Biologics, Inc. Class A